Drug Trial Radar · NCT06461286
SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Oct 31, 2024
Primary completion
Oct 2029
Study completion Nov 2029
Sponsor
- Lead sponsor
- PYC TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A First-in-Human multi-centre, prospective, Phase1a, Single Ascending Dose (SAD) interventional study of PYC-001 in participants with confirmed OPA1 mutation (haploinsufficiency) associated ADOA.
Conditions
- OPA1 Gene Mutation
- Autosomal Dominant Optic Atrophy
- Hereditary Optic Atrophies
- Kjer Optic Atrophy
Interventions
PYC-001Drug
Single Group Assignment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, type, severity and relationship of ocular treatment-emergent adverse events (TEAEs), and treatment-emergent serious adverse events (SAEs) in the study eyeTime frame: 24 weeks
- Incidence, type, severity and relationship of ocular treatment-emergent adverse events (TEAEs), and treatment-emergent serious adverse events (SAEs) in the study eyeTime frame: 48 weeks
- Incidence, type, severity and relationship of ocular TEAEs, and treatment-emergent SAEs in the fellow eyeTime frame: 24 weeks
- Incidence, type, severity and relationship of ocular TEAEs, and treatment-emergent SAEs in the fellow eyeTime frame: 48 weeks
- Incidence, type, severity and relationship of non-ocular TEAEs, and treatment-emergent SAEsTime frame: 24 weeks
- Incidence, type, severity and relationship of non-ocular TEAEs, and treatment-emergent SAEsTime frame: 48 weeks
- Change from baseline for vital signs measurements (heart rate [HR], systolic and diastolic blood pressure [BP], tympanic temperature, respiratory rate [RR])Time frame: 48 weeks
- Change from baseline for 12-lead electrocardiogram (ECG) parametersTime frame: 48 weeks
- Change from baseline for clinical laboratory results - hematologyTime frame: 48 weeks
- Change from baseline for clinical laboratory results - clinical chemistryTime frame: 48 weeks
- Change from baseline for clinical laboratory results - coagulationTime frame: 48 weeks
- Change from baseline for clinical laboratory results - urinalysisTime frame: 48 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Save Sight Institute - Sydney Eye Hospital
Sydney, New South Wales, Australia
Center for Eye Research Australia (CERA)
East Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.